[go: up one dir, main page]

WO1996016652A2 - Utilisation de rifabutine et d'une combinason d'atovacone et de rifabutine dans le traitement d'infections a pneumocystis carinii - Google Patents

Utilisation de rifabutine et d'une combinason d'atovacone et de rifabutine dans le traitement d'infections a pneumocystis carinii Download PDF

Info

Publication number
WO1996016652A2
WO1996016652A2 PCT/GB1995/002790 GB9502790W WO9616652A2 WO 1996016652 A2 WO1996016652 A2 WO 1996016652A2 GB 9502790 W GB9502790 W GB 9502790W WO 9616652 A2 WO9616652 A2 WO 9616652A2
Authority
WO
WIPO (PCT)
Prior art keywords
rifabutin
atovaquone
treatment
carinii
prophylaxis
Prior art date
Application number
PCT/GB1995/002790
Other languages
English (en)
Other versions
WO1996016652A3 (fr
Inventor
John Charles William Comley
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Priority to EP95938501A priority Critical patent/EP0794776A2/fr
Priority to JP8517131A priority patent/JPH10509722A/ja
Priority to AU39871/95A priority patent/AU3987195A/en
Publication of WO1996016652A2 publication Critical patent/WO1996016652A2/fr
Publication of WO1996016652A3 publication Critical patent/WO1996016652A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to synergistic combinations of atovaquone and rifabutin which have activity against. Pneumocystis carinii. More particularly, the invention is concerned with pharmaceutical compositions and their use in the treatment of infections caused by Pneumocystis carinii.
  • Atovaquone 2-[4- ⁇ 4-chlorophenyl)cyclohexyl]-3-hydroxy-1 ,4-naphthoquinone is described in US Patent No. 5053432 and European Patent No. 0123238. It has been described as being useful in the treatment of Pneumocystis carinii, malaria and a number of other protozoal infections.
  • Rifabutin is a semisynthetic ansamycin antibiotic derived from rifamycin S. It has the chemical name 1',4-didehydro-1-deoxy-1,4-dihydro-5 , -(2-methylpropyl)- 1-oxorifamycin XIV (Chemical Abstracts Service, 9th Collective Index) or (9S, 12E, 14S, 15R, 16S, MR, 18R, 19R, 20S, 21 S, 22E, 24Z) - 6,16,18,20 - tetrahydroxy-1 '-isobutyl-14-methoxy-7,9,15,17, 19,21 ,25-heptamethyl- spiro [9,4- (epoxypentadeca[1,11 ,13]trienimino)-2H-furo[2 ⁇ 3 ⁇ :7,8]naphth [1 ,2-c midazole- 2,4 , -piperidine]-5 I 10,26-(3H
  • Rifabutin has activity against My ⁇ bacterium avi ⁇ m complex (MAC) and is commonly used for treatment and prophylaxis of MAC, particularly in patients with AIDS (D.L. Cohn and C.R. Horsburgh, Opportunistic Complication of HIV 2 1, p.6-12 and S. Nightingale et al, New England Journal of Medicine 329 p828- 833). However, it does not have activity against P. carinii infections.
  • MAC My ⁇ bacterium avi ⁇ m complex
  • Combination therapy is advantageous for the treatment of infections since it reduces the likelihood of drug-resistant strains emerging. Where drug combinations are synergistic, it may also be possible to reduce dosages and thus to improve drug tolerance and patient compliance. This is particularly important in immunocompromised patients such as patients with AIDS.
  • the present invention provides a method for the treatment and/or prophylaxis of an infection caused by P. carinii in mammals, including humans, which comprises administering an effective amount of atovaquone or a physiologically acceptable salt thereof and concomitantly or sequentially administering an effective amount of rifabutin.
  • the present invention provides atovaquone for use in the manufacture of a medicament, for administration either concomitantly or sequentially with rifabutin, for treatment and/or prophylaxis of an infection caused by P. carinii, in mammals, including humans.
  • the present invention provides rifabutin for use in the manufacture of a medicament for treatment and/or prophylaxis of an infection caused by P. carinii in mammals including humans.
  • This medicament may be administered either concomitantly or sequentially with atovaquone.
  • Atovaquone and rifabutin are administered concomitantly for treatment and/or prophylaxis of infections caused by P. carinii.
  • Most preferably atovaquone and rifabutin are administered in a potentiating ratio.
  • Atovaquone or a physiologically acceptable salt thereof, and rifabutin wherein atovaquone, or its salt, and rifabutin are present in a potentiating ratio.
  • potentiating ratio' is used herein to indicate that atovaquone and rifabutin are present in a ratio such that the antiparasitic activity of the combination is greater than that of atovaquone alone or of the additive activity that would be predicted for the combination based on the activities of the individual components.
  • the individual components act synergistically in combination provided they are present in a potentiating ratio.
  • a potentiating ratio which may be successfully used to treat Pneumocystis carinii infections is in the range 1:0.1 to 1:100 of atovaquone: rifabutin.
  • the potentiating ratio is in the range 1:0.2 to 1:10.
  • a particularly suitable potentiating ratio is in the range 1 :1 to 1:3.
  • the present invention also provides in another aspect a method for the treatment and/or prophylaxis of Pneumocystis carinii infections in mammals, including humans, which comprises administering an effective amount of a combination of atovaquone, or a physiologically acceptable salt thereof, and rifabutin.
  • the hydroxyl group of atovaquone may form salts with appropriate bases, and physiologically acceptable salts of atovaquone include inorganic base salts such as alkali metal (e.g. sodium and potassium) salts and alkaline earth metal
  • organic base salts e.g. phenylethylbenzylamine, dibenzylethylenediamine, ethanolamine and diethanolamine salts
  • amino acid salts e.g. lysine and arginine
  • the amount of a combination of atovaquone and rifabutin required to be effective against Pneumocystis carinii will, of course, vary and is ultimately at the discretion of the medical practitioner.
  • the factors to be considered include the route of administration and nature of the formulation, the mammal's bodyweight, age and general condition and the nature and severity of the disease to be treated.
  • a suitable effective dose for administration to man for treatment of Pneumocystis carinii infections is in the range of 5mg to 1000mg of atovaquone per kilogram bodyweight per day and 5mg to 1000mg of rifabutin per kilogram bodyweight per day, for example from 10 to 500mg/kg/day of atovaquone and 20 to 500mg/kg/day of rifabutin, particularly 20 to 100mg/kg/day of atovaquone and 20 to 400mg/kg/day of rifabutin.
  • a suitable effective dose for administration to man for prophylaxis of Pneumocystis carinii infections is in the range of from 100 to lOOOOmg per kilogram bodyweight per week of each of atovaquone and rifabutin for example from 200 to 3000mg/kg/week of each of atovaquone and rifabutin.
  • the combination of atovaquone and rifabutin is preferably presented as a pharmaceutical formulation.
  • compositions comprise the active ingredients (that is, the combination of atovaquone and rifabutin) together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic and/or prophylactic ingredients.
  • the carriers must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the present invention provides a pharmaceutical formulation comprising a combination of atovaquone and rifabutin in association with one or more pharmaceutically acceptable carriers therefor.
  • the present invention further provides a process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of atovaquone and rifabutin with one or more pharmaceutically acceptable carriers therefor.
  • a convenient unit dose formulation contains the active ingredients in amounts of from 10mg to 3g each, e.g. 50mg to 3g each.
  • Typical unit doses may contain for example 100mg of atovaquone and 300mg of rifabutin or 50mg of atovaquone and 150mg of rifabutin.
  • compositions include those suitable for oral, rectal and parenteral (including subcutaneous, intradermal, intramuscular and intravenous), administration as well as administration by naso-gastric tube.
  • the formulation may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • compositions suitable for oral administration wherein the carrier is a solid are most preferably presented as unit dose formulations such as boluses, capsules or tablets each containing a predetermined amount of the active ingredients.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active compounds in a free- flowing form such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, lubricating agent, surface-active agent or dispersing agent.
  • Moulded tablets may be made by moulding an inert liquid diluent. Tablets may be optionally coated and, if uncoated, may optionally be scored.
  • Capsules may be prepared by filling the active ingredients, either alone or in admixture with one or more accessory ingredients, into the capsule shells and then sealing them in the usual manner.
  • Cachets are analogous to capsules wherein the active ingredients together with any accessory ingredient(s) are sealed in a rice paper envelope.
  • the combination of atovaquone and rifabutin may also be formulated as dispersible granules, which may for example be suspended in water before administration, or sprinkled on food. The granules may be packaged e.g. in a sachet.
  • Formulations suitable for oral administration wherein the carrier is a liquid may be presented as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion.
  • Formulations for oral administration include controlled release dosage forms, e.g. tablets, wherein the active ingredients are formulated in an appropriate release - controlling matrix, or are coated with a suitable release - controlling film. Such formulations may be particularly convenient for prophylactic use.
  • the active ingredients may also be formulated as a solution or suspension suitable for administration via a naso-gastric tube.
  • compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
  • Suitable carriers include cocoa butter and other materials commonly used in the art.
  • the suppositories may be conveniently formed by admixture of the active combination with the softened or melted carrier(s) followed by chilling and shaping in moulds.
  • compositions suitable for parenteral administration include sterile solutions or suspensions of the active combination in aqueous or oleaginous vehicles.
  • injectible preparations may be adapted for bolus injection or continuous infusion. Such preparations are conveniently presented in unit dose or multi-dose containers which are sealed after introduction of the formulation until required for use.
  • the active ingredients may be in powder form which are constituted with a suitable vehicle, such as sterile, pyrogen-free water, before use.
  • the combination of atovaquone and rifabutin may also be formulated as a long- acting depot preparation, which may be administered by intramuscular injection or by implantation e.g. subcutaneously or intramuscularly.
  • Depot preparations may include, for example, suitable polymeric or hydrophobic materials, or ion- exchange resins. Such long-acting formulations are particularly convenient for prophylactic use.
  • the pharmaceutical formulations for the various routes of administration described above may include, as appropriate one or more additional carrier ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
  • additional carrier ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
  • Acetyl chloride (30g) and finely powdered aluminium chloride (60g) were stirred together in carbon disulphide (120 ml) and then cooled to -50°C, in a C0 2 /oxitol bath.
  • Cyclohexene (30 g) previously cooled to -50°C, was added dropwise during 10 minutes while maintaining the temperature of the reaction mixture at below -20°C. The mixture was stirred at -50°C for a further 60 minutes and the solvent then decanted to leave a gummy orange complex.
  • stage (b) The product of stage (b) was suspended in 10 ml of boiling methanol and 0.55g of potassium hydroxide in 5.5 ml of water was added dropwise over 15 mins. The mixture was refluxed until a dark red solution formed, (after ca. 6 hrs) when 2 ml of concentrated hydrochloric acid was cautiously added dropwise. The mixture was cooled and filtered, and the solid residue washed thoroughly with water. The water washings were re-acidified and filtered. The combined solid residues (500 mg) mp 200-209°, were recrystallised from acetonitrile to give the title product as the trans-isomer (300 mg) m.p. 216-219°C.
  • mice were anaesthetized with halothane, killed by cervical dislocation, the lungs removed en bloc and impression smears prepared.
  • the presence of P. carinii in lung impression smears was rapidly and unambiguously identified by immunofluorescence.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des combinaisons d'atovacone et de rifabutine, leur emploi dans le traitement et la prophylaxie d'infections causées par le P. carinii et leur utilisation dans la fabrication de médicaments pour le traitement et la prophylaxie de ces mêmes infections. Ces combinaisons s'administrent facilement sous forme de préparations pharmaceutiques simples, l'atovacone et la rifabutine s'administrant de préférence dans un rapport de potentialisation leur permettant d'agir en synergie.
PCT/GB1995/002790 1994-11-29 1995-11-29 Utilisation de rifabutine et d'une combinason d'atovacone et de rifabutine dans le traitement d'infections a pneumocystis carinii WO1996016652A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95938501A EP0794776A2 (fr) 1994-11-29 1995-11-29 Utilisation de rifabutine et d'une combinason d'atovacone et de rifabutine dans le traitement d'infections a pneumocystis carinii
JP8517131A JPH10509722A (ja) 1994-11-29 1995-11-29 Ｐｎｅｕｍｏｃｙｓｔｉｓ ｃａｒｉｎｉｉ感染の治療におけるリファブチンの使用およびリファブチンとアトバクオンとの組み合わせ
AU39871/95A AU3987195A (en) 1994-11-29 1995-11-29 Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424013.2 1994-11-29
GB9424013A GB9424013D0 (en) 1994-11-29 1994-11-29 Medicaments

Publications (2)

Publication Number Publication Date
WO1996016652A2 true WO1996016652A2 (fr) 1996-06-06
WO1996016652A3 WO1996016652A3 (fr) 1996-08-15

Family

ID=10765105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/002790 WO1996016652A2 (fr) 1994-11-29 1995-11-29 Utilisation de rifabutine et d'une combinason d'atovacone et de rifabutine dans le traitement d'infections a pneumocystis carinii

Country Status (5)

Country Link
EP (1) EP0794776A2 (fr)
JP (1) JPH10509722A (fr)
AU (1) AU3987195A (fr)
GB (1) GB9424013D0 (fr)
WO (1) WO1996016652A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3107537A4 (fr) * 2014-02-19 2017-09-27 The Texas A&M University System Compositions pour sensibilisation de parasites à un médicament

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
ATE143601T1 (de) * 1993-05-05 1996-10-15 Palo Alto Medical Found Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3107537A4 (fr) * 2014-02-19 2017-09-27 The Texas A&M University System Compositions pour sensibilisation de parasites à un médicament
US10226455B2 (en) 2014-02-19 2019-03-12 The Texas A&M University System Compositions and methods for drug sensitization of parasites

Also Published As

Publication number Publication date
GB9424013D0 (en) 1995-01-18
JPH10509722A (ja) 1998-09-22
WO1996016652A3 (fr) 1996-08-15
AU3987195A (en) 1996-06-19
EP0794776A2 (fr) 1997-09-17

Similar Documents

Publication Publication Date Title
EP0434385B1 (fr) Utilisation des macrocycles contenant de l'azote pour le traitement des infections rétrovirales
JP2005225877A (ja) 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニレン）−１３，１４−ジヒドロ−プロスタグランジンＦ１の使用
AU685408B2 (en) Combination of atovaquone with proguanil for the treatment of protozoal infections
JPH03170475A (ja) 抑うつ症治療剤
US6413993B1 (en) Combination preparation for treating malaria
EP0572615B1 (fr) Medicament destiné au traitement des infections protozoales causées par Babesia
EP0794776A2 (fr) Utilisation de rifabutine et d'une combinason d'atovacone et de rifabutine dans le traitement d'infections a pneumocystis carinii
EP0653936B1 (fr) Utilisation de la 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinone dans le traitement du cancer
EP0496729B1 (fr) Medicament pour le traitement de la cryptosporidiose
JPS61204127A (ja) 抗ウイルス性化合物
HK1004468B (en) Combination of atovaquone with proguanil for the treatment of protozoal infections
HK1041638B (en) Combination preparation for treating malaria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 817880

Date of ref document: 19970501

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995938501

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995938501

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995938501

Country of ref document: EP